Novo Nordisk (NYSE: NVO) shares suffered their sharpest decline in months after the drugmaker’s long-term strategy failed to ease concerns about slowing growth, pricing pressure, and its reliance on semaglutide, even as fresh Phase 3 data gave investors a more favorable look at next-generation obesity candidate CagriSema. Novo’s U.S.-listed shares closed 7.96% lower at $39.80 on Monday, Sept.
Visit Website
